• First-in-human Phase 1 study initiated for investigational antibodies targeting orthopoxviruses developed under U.S. Department of War Accelerated Antibodies Program
• Supports development of countermeasures against orthopoxviruses, a high-priority biological threat family that includes viruses responsible for smallpox
• Delivers integrated process development, regulatory submission and manufacturing of clinical trial material at J.POD® Redmond facility
• Demonstrates scalable model for development and continuous manufacturing for biodefense preparedness

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.